• Lilly boosts immuno-oncology pipeline with $1.6B Armo buy fiercebiotech
    May 16, 2018
    Eli Lilly is ponying up about $1.6 billion to get its hands on Armo Biosciences and its lead asset, pegilodecakin, which has shown promise both as a single agent and in combination treatments for multiple tumor types.
PharmaSources Customer Service